Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS
(Thomson Reuters ONE) -
Nycomed /
Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
ZURICH, Switzerland, and MILAN, Italy, January 12, 2011 - Nycomed, a privately
owned global pharmaceutical company, and Eurand N.V. (NASDAQ: EURX), a global
specialty pharmaceutical company, announced today that Eurand has entered into
an exclusive commercialization, license and supply agreement with Nycomed for
Russia and the Commonwealth of Independent States (CIS), as well as Georgia and
Mongolia. Financial terms were not disclosed.
Under the agreement, Nycomed Russia-CIS will market and distribute ZENPEP®
(pancrelipase) Delayed-Release Capsules in Russia and CIS, as well as Georgia
and Mongolia, subject to regulatory review and approval of the product in those
territories. ZENPEP is an FDA-approved pancreatic enzyme product (PEP)
indicated for the treatment of pancreatic insufficiency in patients with cystic
fibrosis or other conditions, such as chronic pancreatitis, gastrointestinal
surgery and pancreatic cancer. Eurand markets ZENPEP directly in the U.S.
through its own sales force.
"This agreement represents an important development in our international
marketing strategy for ZENPEP," said Andrew Thompson, Eurand's Vice President,
Commercial Operations. "Nycomed is one of the fastest-growing pharmaceutical
companies in Russia, and we are very confident of their ability to maximize the
value of ZENPEP in that market. We look forward to working with Nycomed in
pursuing regulatory approval for this product in the important Russia-CIS
region."
"Nycomed is excited at the prospect of launching ZENPEP into the Russia-CIS
market, where we are launching our recently established gastrointestinal product
portfolio," said Jostein Davidson, Senior Vice President, Nycomed Group, and
President, Nycomed Russia-CIS. "We believe ZENPEP, which has been specifically
formulated to meet the FDA's stringent guidelines for PEPs, will offer
physicians an important new treatment option for their patients with pancreatic
insufficiency."
Russia-CIS is a significant market for PEPs, which is dominated by digestive
disorders such as chronic pancreatitis. According to data provided by IMS
Health Incorporated, the PEP market in this region was estimated to be
approximately
EUR 93.5 million ($130.5 million) in 2009.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and
commercializes enhanced pharmaceutical and biopharmaceutical products based on
its proprietary pharmaceutical technologies. Eurand has had six products
approved by the FDA since 2001 and has a pipeline of product candidates in
development for itself and its collaboration partners. Its technology platforms
include bioavailability enhancement of poorly soluble drugs, custom release
profiles and taste-masking/ orally disintegrating tablet (ODT) formulations.
Eurand is a global company with facilities in the U.S. and Europe. For more
information, visit www.eurand.com.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a differentiated
portfolio focused on branded medicines in gastroenterology, respiratory and
inflammatory diseases, pain, osteoporosis and tissue management. An extensive
range of OTC products completes the portfolio.
Its R&D is structured around partnerships and in-licensing is a cornerstone of
the company's growth strategy.
Nycomed employs 12,000 associates worldwide, and its products are available in
more than 100 countries. It has strong platforms in Europe and in fast-growing
markets such as Russia/CIS and Latin America. While the US and Japan are
commercialised through best-in-class partners, Nycomed plans to further
strengthen its own position in key Asian markets. One of the leading branches of
the Nycomed Group, Nycomed Russia-CIS, operates in more than 120 cities and
regions of Russia and CIS.
Headquartered in Zurich, Switzerland, the company generated total sales of
?3.2 billion in 2009 and an adjusted EBITDA of ?1.1 billion.
For more information visit www.nycomed.com
Eurand Forward-Looking Statement
This release and oral statements made with respect to information contained in
this release, including statements about the market potential of ZENPEP,
constitute forward-looking statements. Such forward-looking statements include
those which express plan, anticipation, intent, contingency, goals, targets or
future development and/or otherwise are not statements of historical fact. The
words "expects", "potentially", "anticipates", "could", "calls for" and similar
expressions also identify forward-looking statements. These statements are based
upon management's current expectations and are subject to risks and
uncertainties, known and unknown, which could cause actual results and
developments to differ materially from those expressed or implied in such
statements. Factors that could affect actual results include, risks associated
with our ability to market, commercialize and achieve market acceptance for
ZENPEP, or for any of the products that we are developing or commercializing or
may develop or commercialize in the future. A non-exclusive list of important
factors that may affect future results may be found in Eurand's filings with the
Securities and Exchange Commission, including its annual report on Form 20-F and
periodic reports on Form 6-K. Investors should evaluate any statement in light
of these important factors. Forward-looking statements contained in this press
release are made as of this date, and we undertake no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise. Actual events could differ materially from those
anticipated in the forward-looking statements.
Contacts:
Beatrix Benz
Media Relations, Nycomed
+41 79 218 98 24
beatrix.benz(at)nycomed.com
Christian B. Seidelin
Investor Relations, Nycomed
+41 44 555 11 04
christian.seidelin(at)nycomed.com
Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
bill.newbould(at)eurand.com
Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
nlaudico(at)theruthgroup.com
--- End of Message ---
Nycomed
Thurgauerstrasse 130 Glattpark-Opfikon Switzerland
Press Release Eurand ZENPEP DE:
http://hugin.info/144179/R/1479185/414901.pdf
Press Release Eurand ZENPEP EN:
http://hugin.info/144179/R/1479185/414900.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nycomed via Thomson Reuters ONE
[HUG#1479185]
Unternehmensinformation / Kurzprofil:
Datum: 12.01.2011 - 13:01 Uhr
Sprache: Deutsch
News-ID 50397
Anzahl Zeichen: 7945
contact information:
Town:
Glattpark-Opfikon
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS"
steht unter der journalistisch-redaktionellen Verantwortung von
Nycomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
